$365亿新“药王”诞生!减肥“神药”领跑,“自免”新星高涨50%,潜力市场冲刺100亿大关

米内网
Yesterday

精彩内容随着各大跨国药企财报披露,2025年全球畅销药TOP10基本尘埃落定。据梳理,TOP1产品销售额、TOP10产品销售额门槛对比2024年均有提升;替尔泊肽全球销售额超365亿美元,首次斩获“药王”宝座,司美格鲁肽以微弱差距排名第二;抗肿瘤赛道大热,帕博利珠单抗、达雷妥尤单抗、纳武利尤单抗成“三足鼎立”之势;自免新星加速崛起,利生奇珠单抗大涨50%;抗凝老将阿哌沙班坚守TOP4,HIV金标准...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10